Atossa Therapeutics Terminates $100 Million At-The-Market (ATM) Offering Program

summarizeSummary

Atossa Therapeutics has terminated its previously established $100 million At-The-Market (ATM) offering facility with Jefferies LLC, effective February 20, 2026, without having sold any shares.

check_boxKey Events

• ATM Program Terminated

  Atossa Therapeutics has formally terminated its $100 million At-The-Market (ATM) offering facility with Jefferies LLC, effective February 20, 2026.

• No Shares Sold

  The company confirmed that no shares were sold under the ATM facility prior to its termination, preventing any dilution from this program.

• Removes Dilution Overhang

  The termination removes the potential for significant future dilution, as the $100 million program was substantial relative to the company's market capitalization.

• Strong Financial Position

  This decision follows recent disclosures of an estimated $40 million in cash and cash equivalents as of year-end 2025, indicating a strong financial runway.

auto_awesomeAnalysis

This termination is a significant positive development for shareholders, as it removes the potential for substantial future dilution. The ATM facility, which allowed for the sale of up to $100 million in common stock, represented a potential capital raise significantly larger than the company's current market capitalization. The decision to terminate the program, especially without having utilized it, suggests the company is confident in its current financial position and does not foresee an immediate need for additional dilutive capital. This aligns with recent positive disclosures, including an estimated $40 million in cash and cash equivalents as of year-end 2025 and progress in clinical trials.